Xiao Feng Duan1, Na Na Dong, Ti Zhang, Qiang Li. 1. Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin, 300060, People's Republic of China.
Abstract
PURPOSE: To evaluate the efficiency of combined treatment of transcatheter arterial chemoembolization (TACE) and systemic chemotherapy (SC) for liver-only metastases from breast cancer after mastectomy. METHODS: We compared the outcomes of 44 patients who underwent combined treatment of TACE and systemic chemotherapy (TSC) with those of 43 patients who underwent systemic chemotherapy (SC). RESULTS: The median follow-up from the diagnosis of liver metastases was 29 months (range, 0-89 months). Response rates were 59.1% and 34.9% for TSC group and SC group (P < 0.05), respectively. The 1-, 2- and 3-year survival rates for TSC group were 76.2, 66.7 and 47.6%, and those for SC group were 48.1, 29.6 and 7.4% (P = 0.027), respectively. Estrogen receptor (ER)-negative status of primary tumor, disease-free interval from mastectomy to liver metastases (DFI) less than 24 months and patients who received systemic chemotherapy only were independently associated with poor prognosis (P = 0.009; P = 0.023; P = 0.030). CONCLUSIONS: The combined treatment of TACE and systemic chemotherapy may prolong survival for liver metastases in breast cancer after mastectomy.
PURPOSE: To evaluate the efficiency of combined treatment of transcatheter arterial chemoembolization (TACE) and systemic chemotherapy (SC) for liver-only metastases from breast cancer after mastectomy. METHODS: We compared the outcomes of 44 patients who underwent combined treatment of TACE and systemic chemotherapy (TSC) with those of 43 patients who underwent systemic chemotherapy (SC). RESULTS: The median follow-up from the diagnosis of liver metastases was 29 months (range, 0-89 months). Response rates were 59.1% and 34.9% for TSC group and SC group (P < 0.05), respectively. The 1-, 2- and 3-year survival rates for TSC group were 76.2, 66.7 and 47.6%, and those for SC group were 48.1, 29.6 and 7.4% (P = 0.027), respectively. Estrogen receptor (ER)-negative status of primary tumor, disease-free interval from mastectomy to liver metastases (DFI) less than 24 months and patients who received systemic chemotherapy only were independently associated with poor prognosis (P = 0.009; P = 0.023; P = 0.030). CONCLUSIONS: The combined treatment of TACE and systemic chemotherapy may prolong survival for liver metastases in breast cancer after mastectomy.
Authors: Tatiana Belda; Eva María Montalvá; Rafael López-Andújar; Eva Rosell; Angel Moya; Inmaculada Gómez; Jose Mir Journal: Cir Esp Date: 2010-09 Impact factor: 1.653
Authors: Martin G Mack; Ralf Straub; Katrin Eichler; Oliver Söllner; Thomas Lehnert; Thomas J Vogl Journal: Radiology Date: 2004-09-30 Impact factor: 11.105
Authors: Tobias F Jakobs; Ralf-Thorsten Hoffmann; Angelika Schrader; Hans Joachim Stemmler; Christoph Trumm; Andreas Lubienski; Ravi Murthy; Thomas K Helmberger; Maximilian F Reiser Journal: Cardiovasc Intervent Radiol Date: 2008-06-25 Impact factor: 2.740
Authors: P Pouillart; M Jouvet; T Palangie; E Garcia-Giralt; B Bretaudeau; T Dorval; B Asselain Journal: Ann Gastroenterol Hepatol (Paris) Date: 1985 Feb-Mar
Authors: Luis H Camacho; Razelle Kurzrock; Alex Cheung; Diane F Barber; Sanjay Gupta; David C Madoff; Michael J Wallace; E Edmund Kim; Steven A Curley; Gabriel N Hortobagyi; Giora Mavligit Journal: Cancer Date: 2007-06-01 Impact factor: 6.860
Authors: Kenneth R Hess; Gauri R Varadhachary; Sarah H Taylor; Wei Wei; Martin N Raber; Renato Lenzi; James L Abbruzzese Journal: Cancer Date: 2006-04-01 Impact factor: 6.860
Authors: B M Aarts; F M Gómez Muñoz; H Wildiers; V O Dezentjé; T R Baetens; W Schats; M Lopez-Yurda; R C Dresen; B J de Wit-van der Veen; C M Deroose; G Maleux; R G H Beets-Tan; E G Klompenhouwer Journal: Cardiovasc Intervent Radiol Date: 2021-07-28 Impact factor: 2.740